Literature DB >> 16204949

Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population.

Asami Kashima1, Miho Funahashi, Kyoko Fukumoto, Kazuo Komamura, Shiro Kamakura, Masafumi Kitakaze, Kazuyuki Ueno.   

Abstract

To evaluate the pharmacokinetic properties and an optimum dose schedule of amiodarone in long-term oral therapy, serum concentrations of amiodarone and its metabolite, desethylamiodarone, were monitored from 345 Japanese inpatients who received amiodarone therapy for a variety of cardiac arrhythmias. Serum amiodarone and desethylamiodarone concentrations were determined by high performance liquid chromatography system. It was observed that the amiodarone and desethylamiodarone concentrations gradually increased with time. The frequency distribution in the amiodarone clearance of 245 subjects, who received fixed maintenance amiodarone therapy for at least 6 months, was nearly a unimodal one. The variation in the ratio of desetylamiodarone to amiodarone concentration in serum was very small. Although no differences in age, dose, dose duration, amiodarone or desethyamiodarone concentration or ratio were observed between men and women: however, the mean amiodarone clearance of women was significantly higer than that of men. The laboratory data were mostly within normal values and no significant relations were observed between serum amiodarone concentration and clinical laboratory data. These results suggest that the individual variation in pharmacokinetics of amiodarone is comparatively small, which might be sufficient to decide that the maintenance dose was the same one (200 mg/d) in long-term oral amiodarone therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16204949     DOI: 10.1248/bpb.28.1934

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  7 in total

1.  Association between N-desethylamiodarone/amiodarone ratio and amiodarone-induced thyroid dysfunction.

Authors:  Mikie Yamato; Kyoichi Wada; Mai Fujimoto; Kouichi Hosomi; Tomohiro Hayashi; Akira Oita; Mitsutaka Takada
Journal:  Eur J Clin Pharmacol       Date:  2017-01-12       Impact factor: 2.953

2.  Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction.

Authors:  Mikie Yamato; Kyoichi Wada; Tomohiro Hayashi; Mai Fujimoto; Kouichi Hosomi; Akira Oita; Mitsutaka Takada
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

3.  Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism.

Authors:  Andrea Hofmann; Clemens Nawara; Sedat Ofluoglu; Johannes Holzmannhofer; Bernhard Strohmer; Christian Pirich
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

4.  Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction.

Authors:  Benjamin Hoemann; Hiroo Takayama; Douglas L Jennings; Jiho Han; Masahiko Ando; Susan Restaino; Paolo Colombo; Maryjane Farr; Yoshifumi Naka; Koji Takeda
Journal:  Clin Transplant       Date:  2020-01-29       Impact factor: 2.863

5.  Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.

Authors:  John K Darby; David J Pasta; Michael G Wilson; John Herbert
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580

Review 6.  Amiodarone: A Newly Discovered Association with Bilateral Vestibulopathy.

Authors:  Robert Gürkov
Journal:  Front Neurol       Date:  2018-03-06       Impact factor: 4.003

7.  Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions.

Authors:  Mirjam Hempenius; Rolf H H Groenwold; Anthonius de Boer; Olaf H Klungel; Helga Gardarsdottir
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-08-02       Impact factor: 2.890

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.